

## Highlights in focus issue on prostate cancer

Eunice X. Xu

Editorial Office, Translational Andrology and Urology, Guangzhou 510120, China

Corresponding to: Eunice X. Xu, Science Editor. Editorial Office, Translational Andrology and Urology, Guangzhou 510120, China. Email: tau@amepc.org.



Submitted Nov 30, 2013. Accepted for publication Dec 11, 2013.

doi: 10.3978/j.issn.1000-9604.2013.12.10

Scan to your mobile device or view this article at: <http://www.thecjcr.org/article/view/3088/3990>

In September 2013, the *Translational Andrology and Urology (TAU)* launched a focus issue on “Prostate Cancer”, which was guest-edited by Dr. Jer-Tsong Hsieh and Dr. Ganesh Raj from University of Texas Southwestern Medical Center at Dallas, USA.

In this focus issue, Dr. Raj and Dr. Hsieh invited an international expert panel of clinicians and basic scientists to outline current challenges of prostate cancer treatment and discuss every aspect of hormonal metabolism, receptor alteration and mechanism in prostate cancer to pave a way for developing better therapeutic strategy and prognostic tools. Also, a wide range of topics such as cancer metastasis, animal model, molecular imaging and targeted therapy of prostate cancer were included as well. Our distinguished contributors are from Tulane University School of Medicine, The Johns Hopkins School of Medicine, Northwestern University and so forth.

*TAU (Transl Androl Urol*; Print ISSN 2223-4683; Online ISSN 2223-4691; [www.amepc.org/tau](http://www.amepc.org/tau)) is an open access, peer reviewed, international journal which publishes articles that describe new findings in the field of translational research of Andrology and Urology, provides current and practical information on basic research, diagnosis, prevention and clinical investigations of Andrology and Urology. Our editor-in-chiefs are Prof. Yinglu Guo, an academican of Chinese Academy of Engineering and an academic leader of Urology and Andrology, and Prof. Tom F. Lue, Vice-Chair of Urology at University of California, San Francisco, USA.

### Outline of the Focus Issue on “Prostate Cancer”

#### ❖ Preface

*Jer-Tsong Hsieh, Ganesh Raj*; Department of Urology, University of Texas Southwestern Medical Center at

Dallas, Dallas, Texas 75390, USA

- ❖ Current clinical challenges in prostate cancer  
*Jonathan L. Silberstein, Sumanta Kumar Pal, Brian Lewis, Oliver Sartor*; Tulane University School of Medicine, 1430 Tulane Ave, Sl-42, New Orleans, LA, USA
- ❖ Androgen receptor gene mutation, rearrangement, polymorphism  
*Kurtis Eisermann, Dan Wang, Yifeng Jing, Laura E. Pascal, Zhou Wang*; Department of Urology, Shadyside Medical Center, Suite G40, 5200 Centre Avenue, Pittsburgh, PA 15232, USA
- ❖ Androgen receptor epigenetics  
*Changmeng Cai, Xin Yuan, Steven P. Balk*; Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
- ❖ Androgen receptor genomic regulation  
*Hong-Fian Jin, Jung Kim, Jindan Yu*; Division of Hematology/Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, 303 E. Superior St. Lurie 5-117, Chicago, IL 60611, USA
- ❖ Decoding the androgen receptor splice variants  
*Changxue Lu, Jun Luo*; The James Buchanan Brady Urological Institute and Department of Urology, The Johns Hopkins School of Medicine. 600 N Wolfe St, 411 Marburg Bldg. Baltimore, MD 21287, USA
- ❖ Androgen receptor-mediated non-genomic regulation of prostate cancer cell proliferation  
*Ross S. Liao, Shibong Ma, Lu Miao, Rui Li, Yi Yin, Ganesh V. Raj*; Department of Urology, The University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9110, USA
- ❖ Translating insights of AR signaling from mouse models

- Brett S. Carver*; Department of Surgery, Division of Urology, Memorial Sloan-Kettering Cancer Center, New York, USA
- ❖ Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression  
*Campbell M. Grant, Natasha Kyprianou*; Departments of Urology, Molecular Biochemistry, and Pathology, University of Kentucky College of Medicine and the Markey Cancer Center, Lexington, Kentucky, USA
  - ❖ Steroid hormone synthetic pathways in prostate cancer  
*Elabe A. Mostagbel*; Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle WA, USA
  - ❖ The role of microRNAs in prostate cancer progression  
*U-Ging Lo, Diane Yang, Jer-Tsong Hsieh*; Departments of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
  - ❖ Cancer stem cells in prostate cancer  
*Felix Moltzahn, George N. Thalmann*; Department of

- Urology, University of Bern, Bern, Switzerland
- ❖ Near-infrared fluorescence and nuclear imaging and targeting of prostate cancer  
*Jason Wu, Dongfeng Pan, Leland W.K. Chung*; Uro-Oncology Research Program, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Department of Radiology, The University of Virginia, Charlottesville, VA 22908, USA
  - ❖ Novel non-AR therapeutic targets in castrate resistant prostate cancer  
*Paul J. Toren, Martin E. Gleave*; Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada

### Acknowledgements

*Disclosure:* The author declares no conflict of interest.

**Cite this article as:** Xu EX. Highlights in focus issue on prostate cancer. *Chin J Cancer Res* 2013;25(6):784-785. doi: 10.3978/j.issn.1000-9604.2013.12.10